Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )

This secondary analysis of the phase 3 ENSEMBLE trial (NCT04505722) assessed the impact of preexisting humoral immunity to adenovirus 26 (Ad26) on the immunogenicity of Ad26.COV2.S-elicited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibody levels in 380 participants in B...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Gars, Mathieu, Sadoff, Jerald, Struyf, Frank, Heerwegh, Dirk, Truyers, Carla, Hendriks, Jenny, Gray, Glenda, Grinsztejn, Beatriz, Goepfert, Paul A, Schuitemaker, Hanneke, Douoguih, Macaya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047246/
https://www.ncbi.nlm.nih.gov/pubmed/35429381
http://dx.doi.org/10.1093/infdis/jiac142
_version_ 1784695683795648512
author Le Gars, Mathieu
Sadoff, Jerald
Struyf, Frank
Heerwegh, Dirk
Truyers, Carla
Hendriks, Jenny
Gray, Glenda
Grinsztejn, Beatriz
Goepfert, Paul A
Schuitemaker, Hanneke
Douoguih, Macaya
author_facet Le Gars, Mathieu
Sadoff, Jerald
Struyf, Frank
Heerwegh, Dirk
Truyers, Carla
Hendriks, Jenny
Gray, Glenda
Grinsztejn, Beatriz
Goepfert, Paul A
Schuitemaker, Hanneke
Douoguih, Macaya
author_sort Le Gars, Mathieu
collection PubMed
description This secondary analysis of the phase 3 ENSEMBLE trial (NCT04505722) assessed the impact of preexisting humoral immunity to adenovirus 26 (Ad26) on the immunogenicity of Ad26.COV2.S-elicited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibody levels in 380 participants in Brazil, South Africa, and the United States. Among those vaccinated in Brazil and South Africa, 31% and 66%, respectively, had prevaccination serum-neutralizing activity against Ad26, with little preexisting immunity detected in the United States. Vaccine recipients in each country had similar postvaccination spike (S) protein–binding antibody levels, indicating that baseline immunity to Ad26 has no clear impact on vaccine-induced immune responses.
format Online
Article
Text
id pubmed-9047246
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90472462022-04-28 Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( ) Le Gars, Mathieu Sadoff, Jerald Struyf, Frank Heerwegh, Dirk Truyers, Carla Hendriks, Jenny Gray, Glenda Grinsztejn, Beatriz Goepfert, Paul A Schuitemaker, Hanneke Douoguih, Macaya J Infect Dis Brief Report This secondary analysis of the phase 3 ENSEMBLE trial (NCT04505722) assessed the impact of preexisting humoral immunity to adenovirus 26 (Ad26) on the immunogenicity of Ad26.COV2.S-elicited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibody levels in 380 participants in Brazil, South Africa, and the United States. Among those vaccinated in Brazil and South Africa, 31% and 66%, respectively, had prevaccination serum-neutralizing activity against Ad26, with little preexisting immunity detected in the United States. Vaccine recipients in each country had similar postvaccination spike (S) protein–binding antibody levels, indicating that baseline immunity to Ad26 has no clear impact on vaccine-induced immune responses. Oxford University Press 2022-04-16 /pmc/articles/PMC9047246/ /pubmed/35429381 http://dx.doi.org/10.1093/infdis/jiac142 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Le Gars, Mathieu
Sadoff, Jerald
Struyf, Frank
Heerwegh, Dirk
Truyers, Carla
Hendriks, Jenny
Gray, Glenda
Grinsztejn, Beatriz
Goepfert, Paul A
Schuitemaker, Hanneke
Douoguih, Macaya
Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
title Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
title_full Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
title_fullStr Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
title_full_unstemmed Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
title_short Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
title_sort impact of preexisting anti–adenovirus 26 humoral immunity on immunogenicity of the ad26.cov2.s coronavirus disease 2019 vaccine( )
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047246/
https://www.ncbi.nlm.nih.gov/pubmed/35429381
http://dx.doi.org/10.1093/infdis/jiac142
work_keys_str_mv AT legarsmathieu impactofpreexistingantiadenovirus26humoralimmunityonimmunogenicityofthead26cov2scoronavirusdisease2019vaccine
AT sadoffjerald impactofpreexistingantiadenovirus26humoralimmunityonimmunogenicityofthead26cov2scoronavirusdisease2019vaccine
AT struyffrank impactofpreexistingantiadenovirus26humoralimmunityonimmunogenicityofthead26cov2scoronavirusdisease2019vaccine
AT heerweghdirk impactofpreexistingantiadenovirus26humoralimmunityonimmunogenicityofthead26cov2scoronavirusdisease2019vaccine
AT truyerscarla impactofpreexistingantiadenovirus26humoralimmunityonimmunogenicityofthead26cov2scoronavirusdisease2019vaccine
AT hendriksjenny impactofpreexistingantiadenovirus26humoralimmunityonimmunogenicityofthead26cov2scoronavirusdisease2019vaccine
AT grayglenda impactofpreexistingantiadenovirus26humoralimmunityonimmunogenicityofthead26cov2scoronavirusdisease2019vaccine
AT grinsztejnbeatriz impactofpreexistingantiadenovirus26humoralimmunityonimmunogenicityofthead26cov2scoronavirusdisease2019vaccine
AT goepfertpaula impactofpreexistingantiadenovirus26humoralimmunityonimmunogenicityofthead26cov2scoronavirusdisease2019vaccine
AT schuitemakerhanneke impactofpreexistingantiadenovirus26humoralimmunityonimmunogenicityofthead26cov2scoronavirusdisease2019vaccine
AT douoguihmacaya impactofpreexistingantiadenovirus26humoralimmunityonimmunogenicityofthead26cov2scoronavirusdisease2019vaccine

Ejemplares similares